A PYMNTS Company

EU To Probe Johnson & Johnson’s Takeda Deal

By  |  March 25, 2020

EU antitrust regulators have opened a full investigation into Johnson & Johnson’s acquisition of Takeda Pharmaceutical’s surgical patch product TachoSil, concerned that the deal could lead to reduced choice and higher prices for customers.

    Get the Full Story

    Complete the form to unlock this article and enjoy unlimited free access to all PYMNTS content — no additional logins required.

    yesSubscribe to our daily newsletter, PYMNTS Today.

    By completing this form, you agree to receive marketing communications from PYMNTS and to the sharing of your information with our sponsor, if applicable, in accordance with our Privacy Policy and Terms and Conditions.

    Takeda, Japan’s biggest drugmaker, announced the sale of TachoSil, a surgical patch for bleeding control, to US giant Johnson & Johnson’s subsidiary Ethicon for $400 million last March, reported Reuters.

    The European Commission said a preliminary investigation found cause for concern because TachoSil is the market leader in Europe. Johnson & Johnson is also a major maker of surgical patches globally although it does not sell such dual patches in Europe.

    The EU competition enforcer said high development costs meant rivals would find it difficult to enter the market.

    “In this concentrated space, we need to carefully assess whether the proposed merger would lead to reduced choice for surgeons and patients, to higher prices for our health services, or to slower development of alternative solutions to manage problematic bleeding,” European Competition Commissioner Margrethe Vestager said in a statement.

    Full Content: Reuters

    Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.